700 Targeting SIRT/CD38/NAD+ Homeostasis to Mitigate Fibrosis in Scleroderma

Journal of Investigative Dermatology - United Kingdom
doi 10.1016/j.jid.2019.03.776
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Targeting miR-155 to Treat Experimental Scleroderma

Scientific Reports
Multidisciplinary
2016English

Targeting CD38 Alleviates Tumor-Induced Immunosuppression

Oncotarget
Oncology
2017English

Role of Endoglin in Fibrosis and Scleroderma

International Review of Cell and Molecular Biology
BiochemistryCell BiologyMolecular Biology
2012English

CD38-NAD + Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response

Cell Metabolism
Cell BiologyMolecular BiologyPhysiology
2018English

Targeting the Hedgehog Pathway to Mitigate Treatment Resistance

Cell Cycle
MedicineDevelopmental BiologyCell BiologyMolecular Biology
2007English

Targeting CD38 in the Tumor Microenvironment; A Novel Approach to Treat Glioma

Cancer Cell & Microenvironment
2015English

Scleroderma Lung Fibrosis and Biologic Drugs

Rheumatology : Current Research
2012English

Monoclonal Antibodies Targeting CD38 in Hematological Malignancies and Beyond

Immunological Reviews
AllergyImmunology
2016English

Dynamic Conformations of the CD38-Mediated NAD Cyclization Captured in a Single Crystal

Journal of Molecular Biology
Structural BiologyMolecular BiologyBiophysics
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy